The Lyn kinase activator MLR-1023 is a novel insulin receptor potentiator that elicits a rapid-onset and durable improvement in glucose homeostasis in animal models of type 2 diabetes

Journal of Pharmacology and Experimental Therapeutics

Volumn 342, Issue 1, 2012, Pages 23-32

  Ochman, Alexander R ^a   Lipinski, Christopher A ^b   Handler, Jeffrey A ^c   Reaume, Andrew G ^a   Saporito, Michael S ^a  

^a Melior Discovery Inc   (United States)

^b Melior Discovery Inc   (United States)

^c JAH Associates   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE; HEMOGLOBIN A1C; INSULIN; INSULIN RECEPTOR; INSULIN SENSITIZING AGENT; METFORMIN; MLR 1023; PROTEIN KINASE LYN; ROSIGLITAZONE; STREPTOZOCIN; TOLIMIDONE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG POTENTIATION; GLUCOSE BLOOD LEVEL; GLUCOSE HOMEOSTASIS; GLUCOSE INFUSION; INSULIN BLOOD LEVEL; MALE; MOUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; ORAL GLUCOSE TOLERANCE TEST; PANCREAS ISLET BETA CELL; PRIORITY JOURNAL; RAT; RECEPTOR SENSITIVITY; STREPTOZOCIN DIABETES;

ANIMALS; BLOOD GLUCOSE; DIABETES MELLITUS, EXPERIMENTAL; DIABETES MELLITUS, TYPE 2; GLUCOSE TOLERANCE TEST; HOMEOSTASIS; HYPOGLYCEMIC AGENTS; INSULIN; INSULIN-SECRETING CELLS; MALE; MICE; MICE, INBRED ICR; PYRIMIDINONES; RATS; RECEPTOR, INSULIN; SRC-FAMILY KINASES;

EID: 84862492511     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.112.192187     Document Type: Article

References (36)

1. Ajjan RA and Grant PJ (2008) The cardiovascular safety of rosiglitazone. Expert Opin Drug Saf 7:367-376.
2. Anderwald C, Müller G, Koca G, Fürnsinn C, Waldhäusl W, and Roden M (2002) Short-term leptin-dependent inhibition of hepatic gluconeogenesis is mediated by insulin receptor substrate-2. Mol Endocrinol 16:1612-1628. (Pubitemid 34743678)
3. Baribault H (2010) Mouse models of type II diabetes mellitus in drug discovery. Methods Mol Biol 602:135-155.
4. Bergenstal RM, Wysham C, Macconell L, Malloy J, Walsh B, Yan P, Wilhelm K, Malone J, Porter LE, and DURATION-2 Study Group (2010) Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial. Lancet 376:431-439.
5. Bloomgarden ZT (2006) Measures of insulin sensitivity. Clin Lab Med 26:611-633, vi.
6. Connor SC, Hughes MG, Moore G, Lister CA, and Smith SA (1997) Antidiabetic efficacy of BRL 49653, a potent orally active insulin sensitizing agent, assessed in the C57BL/KsJ db/db diabetic mouse by non-invasive 1H NMR studies of urine. J Pharm Pharmacol 49:336-344. (Pubitemid 27197026)
7. DeFronzo RA (2010) Current issues in the treatment of type 2 diabetes. Overview of newer agents: where treatment is going. Am J Med 123:S38-S48.
8. DeFronzo RA and Abdul-Ghani M (2011a) Type 2 diabetes can be prevented with early pharmacological intervention. Diabetes Care 34 (Suppl 2):S202-S209.
9. DeFronzo RA and Abdul-Ghani MA (2011b) Preservation of β-cell function: the key to diabetes prevention. J Clin Endocrinol Metab 96:2354-2366.
10. Fujita H, Fujishima H, Koshimura J, Hosoba M, Yoshioka N, Shimotomai T, Morii T, Narita T, Kakei M, and Ito S (2005) Effects of antidiabetic treatment with metformin and insulin on serum and adipose tissue adiponectin levels in db/db mice. Endocr J 52:427-433. (Pubitemid 41380551)
11. Harder KW, Parsons LM, Armes J, Evans N, Kountouri N, Clark R, Quilici C, Grail D, Hodgson GS, Dunn AR, et al. (2001) Gain- and loss-of-function Lyn mutant mice define a critical inhibitory role for Lyn in the myeloid lineage. Immunity 15:603-615. (Pubitemid 33016445)
12. Harrington WW, Britt C, Wilson J, Milliken N, Binz J, Lobe D, Oliver W, Lewis M, and Ignar D (2007) The effect of PPARα, PPARδ, PPARγ, and PPARpan agonists on body weight, body mass, and serum lipid profiles in diet-induced obese AKR/J mice. PPAR Res 2007:97125.
13. Hundal RS, Krssak M, Dufour S, Laurent D, Lebon V, Chandramouli V, Inzucchi SE, Schumann WC, Petersen KF, Landau BR, et al. (2000) Mechanism by which metformin reduces glucose production in type 2 diabetes. Diabetes 49:2063-2069.
14. Kahn SE (2003) The relative contributions of insulin resistance and beta-cell dysfunction to the pathophysiology of Type 2 diabetes. Diabetologia 46:3-19.
15. Kawasaki F, Matsuda M, Kanda Y, Inoue H, and Kaku K (2005) Structural and functional analysis of pancreatic islets preserved by pioglitazone in db/db mice. Am J Physiol Endocrinol Metab 288:E510-E518. (Pubitemid 40250545)
16. Kolb H (1987) Mouse models of insulin dependent diabetes: low-dose streptozocin-induced diabetes and nonobese diabetic (NOD) mice. Diabetes Metab Rev 3:751-778.
17. Kramer D, Shapiro R, Adler A, Bush E, and Rondinone CM (2001) Insulin-sensitizing effect of rosiglitazone (BRL-49653) by regulation of glucose transporters in muscle and fat of Zucker rats. Metabolism 50:1294-1300. (Pubitemid 34007388)
18. Lipinski CA, Stam JG, Pereira JN, Ackerman NR, and Hess HJ (1980) Bronchodilator and antiulcer phenoxypyrimidinones. J Med Chem 23:1026-1031. (Pubitemid 11170636)
19. Moore MC, Connolly CC, and Cherrington AD (1998) Autoregulation of hepatic glucose production. Eur J Endocrinol 138:240-248. (Pubitemid 28154768)
20. Mu J, Petrov A, Eiermann GJ, Woods J, Zhou YP, Li Z, Zycband E, Feng Y, Zhu L, Roy RS, et al. (2009) Inhibition of DPP-4 with sitagliptin improves glycemic control and restores islet cell mass and function in a rodent model of type 2 diabetes. Eur J Pharmacol 623:148-154.
21. Mu J, Woods J, Zhou YP, Roy RS, Li Z, Zycband E, Feng Y, Zhu L, Li C, Howard AD, et al. (2006) Chronic inhibition of dipeptidyl peptidase-4 with a sitagliptin analog preserves pancreatic beta-cell mass and function in a rodent model of type 2 diabetes. Diabetes 55:1695-1704. (Pubitemid 44324122)
22. Müller G, Schulz A, Wied S, and Frick W (2005) Regulation of lipid raft proteins by glimepiride- and insulin-induced glycosylphosphatidylinositol- specific phospholipase C in rat adipocytes. Biochem Pharmacol 69:761-780. (Pubitemid 40248619)
23. National Institutes of Health (1985) Principles of Laboratory Animal Care, NIH publication 85-23, revised. National Institutes of Health, Bethesda.
24. Müller G, Wied S, and Frick W (2000) Cross talk of pp125(FAK) and pp59(Lyn) non-receptor tyrosine kinases to insulin-mimetic signaling in adipocytes. Mol Cell Biol 20:4708-4723. (Pubitemid 30396118)
25. Palmer AJ, Roze S, Valentine WJ, Minshall ME, Lammert M, Nicklasson L, and Spinas GA (2004) Deleterious effects of increased body weight associated with intensive insulin therapy for type 1 diabetes: increased blood pressure and worsened lipid profile partially negate improvements in life expectancy. Curr Med Res Opin 20 (Suppl 1):S67-S73. (Pubitemid 39349910)
26. Petersen KF and Shulman GI (2006) Etiology of insulin resistance. Am J Med 119:S10-S16.
27. Phung OJ, Scholle JM, Talwar M, and Coleman CI (2010) Effect of noninsulin antidiabetic drugs added to metformin therapy on glycemic control, weight gain, and hypoglycemia in type 2 diabetes. JAMA 303:1410-1418.
28. Rosen ED and Spiegelman BM (2001) PPARgamma: a nuclear regulator of metabolism, differentiation, and cell growth. J Biol Chem 276:37731-37734.
29. Saporito MS, Lipinski CA, and Reaume A (2012a) Phenotypic in vivo screening to identify new, unpredicted indications for existing drugs and drug candidates, in Drug Repositioning: Bringing New Life to Shelved Assets (Barratt MJ and Frail D eds) pp 253-280, John Wiley & Sons, Hoboken.
30. Saporito MS, Ochman AR, Lipinski CA, Handler JA, and Reaume AG (2012b) MLR-1023 is a potent and selective allosteric activator of lyn kinase in vitro that improves glucose tolerance in vivo. J Pharmacol Exp Ther 342:15-22.
31. Sears DD, Hsiao G, Hsiao A, Yu JG, Courtney CH, Ofrecio JM, Chapman J, and Subramaniam S (2009) Mechanisms of human insulin resistance and thiazolidinedione-mediated insulin sensitization. Proc Natl Acad Sci USA 106:18745-18750.
32. Shaw RJ, Lamia KA, Vasquez D, Koo SH, Bardeesy N, Depinho RA, Montminy M, and Cantley LC (2005) The kinase LKB1 mediates glucose homeostasis in liver and therapeutic effects of metformin. Science 310:1642-1646. (Pubitemid 41780780)
33. Stoffers DA, Kieffer TJ, Hussain MA, Drucker DJ, Bonner-Weir S, Habener JF, and Egan JM (2000) Insulinotropic glucagon-like peptide 1 agonists stimulate expression of homeodomain protein IDX-1 and increase islet size in mouse pancreas. Diabetes 49:741-748. (Pubitemid 30339989)
34. Young AA, Gedulin BR, Bhavsar S, Bodkin N, Jodka C, Hansen B, and Denaro M (1999) Glucose-lowering and insulin-sensitizing actions of exendin-4: studies in obese diabetic (ob/ob, db/db) mice, diabetic fatty Zucker rats, and diabetic rhesus monkeys (Macaca mulatta). Diabetes 48:1026-1034. (Pubitemid 29226349)
35. Zhang B, Graziano MP, Doebber TW, Leibowitz MD, White-Carrington S, Szalkowski DM, Hey PJ, Wu M, Cullinan CA, Bailey P, et al. (1996) Downregulation of the expression of the obese gene by an antidiabetic thiazolidinedione in Zucker diabetic fatty rats and db/db mice. J Biol Chem 271:9455-9459. (Pubitemid 26139923)
36. Zhang LN, Mitchell SE, Hambly C, Morgan DG, Clapham JC, and Speakman JR (2012) Physiological and behavioral responses to intermittent starvation in C57BL/6J mice. Physiol Behav 105:376-387.